Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
Salarius Pharmaceuticals (NASDAQ:SLRX) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Salarius Pharmaceuticals (NASDAQ:SLRX) is now covered by analysts at
Weiss Ratings. They set a "sell (e+)" rating on the stock.
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” [Yahoo! Finance]
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX”